PRDM16 can bind SMAD proteins and is known to inhibit the TGF-β pathway during embryonic development in the skeletal system and during cancer.8,10 Likewise, numerous studies have indicated that the cardiac phenotypes downstream of perturbed PRDM16 signalling are—at least partly—attributable to alterations in TGF-β signalling. The gene discussed is PRDM16; the disease is cancer.